ArticleJAR life2025
The role of multivitamins and minerals (MVM) supplementation in dementia risk reduction for older people in Taiwan: Insights from a population health and economic model.
Article in JAR life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To estimate the potential health and economic impact of regular multivitamin and mineral (MVM) supplementation in reducing dementia risk among Taiwanese adults aged ≥ 60 years old. Methods: A population-based health economic model was developed to project dementia-related health and economic outcomes over a 10-year period (2024-2033) under two scenarios: current lack of MVM use versus expanded regular use (≥3 times/week). Model inputs were derived from Taiwanese demographic, epidemiological, and cost data, supplemented by published trials and expert validation. Outcomes included dementia cases prevented, premature deaths averted, years of life lost (YLL) averted, years lived with disability (YLD) averted, quality-adjusted life years (QALYs) gained, and societal cost savings from reductions in direct medical, non-medical, and caregiver-related costs. Results: Regular MVM use was projected to prevent 204,250 dementia cases and 23,649 premature deaths, gain 407,910 QALYs, avert 115,943 YLL and 597,978 YLD. Total cost savings were estimated at NT$1.41 trillion, comprising NT$1.19 trillion in direct costs and NT$220 billion in indirect costs. Sensitivity analysis identified dementia risk reduction of MVM supplementation as the most influential parameter, but benefits remained robust under conservative assumptions. Conclusion: Regular MVM supplementation among older Taiwanese adults without prior MVM use could meaningfully reduce dementia burden and generate substantial healthcare and societal cost savings. These findings highlight regular MVM use as a pragmatic strategy to support cognitive health in aging populations and provide a transferable modelling framework for other Asia-Pacific settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.